Cost-effectiveness of a government rebate program for air cleaners in preventing asthma and related adverse health outcomes

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

Wildfire-derived fine particulate matter (PM 2.5 ) is an increasing contributor to air pollution in British Columbia (BC), Canada, and is linked to asthma development and asthma-related adverse outcomes including exacerbations. Portable high-efficiency particulate air (HEPA) cleaners can reduce indoor PM 2.5 , but evidence on their long-term, population-level cost-effectiveness is limited.

Methods

We developed a monthly, time-varying Markov cohort model (2010–2035; healthcare payer perspective; 1.5% annual discounting; $50,000/QALY willingness-to-pay) for two BC cohorts (age 5 and age 25 at baseline) across 16 Health Service Delivery Areas (HSDAs). The model simulated monthly transitions between health states (well-controlled asthma, not well-controlled asthma, exacerbations, and death) over a 25-year time horizon (2010–2035). The target population was children age 5 and adults aged 25 (separate cohorts). We combined historical total PM 2.5 (2010–2022) from provincial data sources with projected PM 2.5 (2023–2035) combining anthropogenic emissions with wildfire-derived PM 2.5 . Wildfire PM 2.5 projections were calculated by multiplying monthly PM 2.5 averages from 2018–2022 by 0%, 5.5%, and 11% cumulative PM 2.5 increase scenarios, informed by climate modeling. The base-case rebate was $150, and varied rebates between $50 to $200. We assumed continuous use with unit replacement every 5 years and filter replacement every 9 months. We calculated asthma incidence attributable to wildfire PM 2.5 and incremental cost-effectiveness ratios (ICERs) across BC’s 16 Health Service Delivery Areas (HSDAs). We conducted the analysis from a health payer perspective with a 1.5% discount rate and $50,000/QALY willingness to pay threshold. Costs are expressed in 2024 CAD.

Results

From 2023–2036, wildfire-derived PM 2.5 was associated with 13–14 incident asthma cases per 100,000 person-years annually across BC. Over 25 years, air cleaners prevented 444 moderate exacerbations, 55 emergency department visits, and 42 hospitalizations (combined cohorts), but the base-case program was not cost-effective in any HSDA (ICER range: $149,408–$154,749/QALY). A $50 rebate was cost-effective province-wide and $100 was cost-effective in three HSDAs. Results were most sensitive to concentration-response functions for PM2.5 (incidence, control, exacerbations) and to HEPA air cleaner and asthma care costs. Cost-effectiveness was most sensitive to air cleaner costs and the concentration-response function between PM 2.5 and asthma incidence.

Conclusions

Wildfire-related PM 2.5 contributes meaningfully to asthma incidence in BC. A universal $150 HEPA rebate program was not cost-effective for primary prevention under base-case assumptions, whereas lower rebates ($50 province-wide, $100 in three HSDAs) may offer better value. Future evaluations should co-benefits across multiple disease outcomes to better support policies to reduce the health impacts of increasing wildfires.

Article activity feed